These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
985 related articles for article (PubMed ID: 34740598)
1. Increased complications of COVID-19 in people with cardiovascular disease: Role of the renin-angiotensin-aldosterone system (RAAS) dysregulation. Augustine R; S A; Nayeem A; Salam SA; Augustine P; Dan P; Maureira P; Mraiche F; Gentile C; Hansbro PM; McClements L; Hasan A Chem Biol Interact; 2022 Jan; 351():109738. PubMed ID: 34740598 [TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications. Groß S; Jahn C; Cushman S; Bär C; Thum T J Mol Cell Cardiol; 2020 Jul; 144():47-53. PubMed ID: 32360703 [TBL] [Abstract][Full Text] [Related]
4. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). Bourgonje AR; Abdulle AE; Timens W; Hillebrands JL; Navis GJ; Gordijn SJ; Bolling MC; Dijkstra G; Voors AA; Osterhaus AD; van der Voort PH; Mulder DJ; van Goor H J Pathol; 2020 Jul; 251(3):228-248. PubMed ID: 32418199 [TBL] [Abstract][Full Text] [Related]
5. Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors and Coronavirus Disease 2019 (COVID-19). Albashir AAD South Med J; 2021 Jan; 114(1):51-56. PubMed ID: 33398362 [TBL] [Abstract][Full Text] [Related]
6. What solid organ transplant healthcare providers should know about renin-angiotensin-aldosterone system inhibitors and COVID-19. Wong SY; Brubaker AL; Wang AX; Taiwo AA; Melcher ML Clin Transplant; 2020 Jul; 34(7):e13991. PubMed ID: 32446267 [TBL] [Abstract][Full Text] [Related]
7. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update. Shukla AK; Banerjee M High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533 [TBL] [Abstract][Full Text] [Related]
9. Renin-angiotensin-aldosterone system peptide profiles in patients with COVID-19. Kutz A; Conen A; Gregoriano C; Haubitz S; Koch D; Domenig O; Bernasconi L; Mueller B; Schuetz P Eur J Endocrinol; 2021 Apr; 184(4):543-552. PubMed ID: 33539316 [TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical and Transcriptional Analysis of SARS-CoV-2 Entry Factors and Renin-Angiotensin-Aldosterone System Components in Lethal COVID-19. Haslbauer JD; Stalder A; Zinner C; Bassetti S; Mertz KD; Went P; Matter M; Tzankov A Pathobiology; 2022; 89(3):166-177. PubMed ID: 34915500 [TBL] [Abstract][Full Text] [Related]
11. Coronavirus Disease 2019 and Hypertension: The Role of Angiotensin-Converting Enzyme 2 and the Renin-Angiotensin System. Edmonston DL; South AM; Sparks MA; Cohen JB Adv Chronic Kidney Dis; 2020 Sep; 27(5):404-411. PubMed ID: 33308506 [TBL] [Abstract][Full Text] [Related]
12. Cardiovascular aspects of COVID-19. Kurz DJ; Eberli FR Swiss Med Wkly; 2020 Dec; 150():w20417. PubMed ID: 33382450 [TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 and hypertension. Ravichandran B; Grimm D; Krüger M; Kopp S; Infanger M; Wehland M Physiol Rep; 2021 Jun; 9(11):e14800. PubMed ID: 34121359 [TBL] [Abstract][Full Text] [Related]
14. Serum ACE2, Angiotensin II, and Aldosterone Levels Are Unchanged in Patients With COVID-19. Rieder M; Wirth L; Pollmeier L; Jeserich M; Goller I; Baldus N; Schmid B; Busch HJ; Hofmann M; Kern W; Bode C; Duerschmied D; Lother A Am J Hypertens; 2021 Apr; 34(3):278-281. PubMed ID: 33043967 [TBL] [Abstract][Full Text] [Related]
15. Anti-inflammatory drugs and the renin-angiotensin-aldosterone system: Current knowledge and potential effects on early SARS-CoV-2 infection. Cabbab ILN; Manalo RVM Virus Res; 2021 Jan; 291():198190. PubMed ID: 33039544 [TBL] [Abstract][Full Text] [Related]
16. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial. Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924 [TBL] [Abstract][Full Text] [Related]
17. Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities. Wang JJ; Edin ML; Zeldin DC; Li C; Wang DW; Chen C Pharmacol Ther; 2020 Nov; 215():107628. PubMed ID: 32653530 [TBL] [Abstract][Full Text] [Related]
18. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. Sama IE; Ravera A; Santema BT; van Goor H; Ter Maaten JM; Cleland JGF; Rienstra M; Friedrich AW; Samani NJ; Ng LL; Dickstein K; Lang CC; Filippatos G; Anker SD; Ponikowski P; Metra M; van Veldhuisen DJ; Voors AA Eur Heart J; 2020 May; 41(19):1810-1817. PubMed ID: 32388565 [TBL] [Abstract][Full Text] [Related]
19. Intrinsic disorder perspective of an interplay between the renin-angiotensin-aldosterone system and SARS-CoV-2. Elrashdy F; Redwan EM; Uversky VN Infect Genet Evol; 2020 Nov; 85():104510. PubMed ID: 32853823 [TBL] [Abstract][Full Text] [Related]
20. Effects of SARS-CoV-2 on Cardiovascular System: The Dual Role of Angiotensin-Converting Enzyme 2 (ACE2) as the Virus Receptor and Homeostasis Regulator-Review. Aleksova A; Gagno G; Sinagra G; Beltrami AP; Janjusevic M; Ippolito G; Zumla A; Fluca AL; Ferro F Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33926110 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]